# STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: **Understanding Long-COVID to Address and Transform Existing Integrated Care** Pathways Delphi): Study protocol.

Authors: Christina M. van der Feltz-Cornelis<sup>1, 2, 3</sup>, Jennifer Sweetman<sup>1</sup>, Gail Allsopp<sup>4,,5</sup>, Emily Attree<sup>6</sup>, Michael G. Crooks<sup>7,8</sup>, Daniel J Cuthbertson<sup>9</sup>, Denise Forshaw<sup>10</sup>, Mark Gabbay<sup>11,12</sup>, Angela Green<sup>8</sup>, Melissa Heightman<sup>13</sup>, Toby Hillman<sup>13,14</sup>, Lyth Hishmeh<sup>15</sup>, Kamlesh Khunti<sup>16</sup>, Gregory Y.H. Lip<sup>17,18</sup>, Paula Lorgelly<sup>19,20</sup>, Hugh Montgomery<sup>21</sup>, W. David Strain<sup>22</sup>, Emma Wall<sup>23,24</sup>, Caroline Watkins<sup>10, 25</sup>, Nefyn Williams<sup>26</sup>, Dan G. Wootton<sup>27,28</sup>, Amitava Banerjee<sup>3,29</sup> for the STIMULATE-ICP Consortium.

Corresponding author: Christina van der Feltz-Cornelis, Dept. of Health Sciences, HYMS, University of York, ARRC Building, T204, Heslington, York, United Kingdom Phone: +443219041313 Email: christina.vanderfeltz-cornelis@vork.ac.uk

- <sup>1</sup> Dept of Health Sciences, University of York, York, United Kingdom
- <sup>2</sup> Hull York Medical School, (HYMS), University of York, York, United Kingdom
- <sup>3</sup> Institute of Health Informatics, University College London, London, United Kingdom
- <sup>4</sup> Royal College of General Practitioners, London, United Kingdom
- <sup>5</sup> National Institute of Health and Care Excellence, United Kingdom
- <sup>6</sup>CCG NHS Camden, London, United Kingdom
- <sup>7</sup> Hull York Medical School, University of Hull, Hull, United Kingdom
- <sup>8</sup> Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
- <sup>9</sup>Institute of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK
- <sup>10</sup>Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom
- <sup>11</sup> Department of Primary Care & Mental Health, University of Liverpool, Liverpool, United Kingdom
- <sup>12</sup>NIHR ARC NWC, Liverpool, United Kingdom
- <sup>13</sup> Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom
- <sup>14</sup>UCL Respiratory, University College London, London, United Kingdom
- <sup>15</sup>Long COVID SOS, Oxford, United Kingdom
- <sup>16</sup> Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, United Kingdom
- <sup>17</sup> Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital. Liverpool, United Kingdom
- <sup>18</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- <sup>19</sup> School of Population Health and Department of Economics, University of Auckland, New Zealand
- <sup>20</sup> Institute of Epidemiology and Health Care, University College London, London, United Kingdom
- <sup>21</sup> Department of Medicine, University College London, London, United Kingdom
- <sup>22</sup> Diabetes and Vascular Medicine Research Centre, Institute of Biomedical and Clinical Science and College of Medicine and Health, University of Exeter, Exeter, UK
- <sup>23</sup> Francis Crick Institute, 1, Midland Road, London, United Kingdom
- <sup>24</sup> National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, United Kingdom
- <sup>25</sup> Faculty of Health and Care, University of Central Lancashire, Preston, United Kingdom
- <sup>26</sup>. Department of Primary Care and Mental Health, University of Liverpool, Liverpool, United Kingdom
- <sup>27</sup> Institute of Infection Veterinary and Ecological Sciences and NIHR HPRU in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom
- <sup>28</sup>Liverpool University Hospitals NHS Foundation Trust, United Kingdom
- <sup>29</sup> Department of Cardiology, University College London Hospitals NHS Trust, London, United Kingdom

### Word count: 3,541

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### Metadata

#### **Financial disclosure statement**

This research is funded by NIHR (COV-LT2-0043) as part of the STIMULATE-ICP study. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care.

### **Competing Interests statement**

EA is clinical lead in a Quality Improvement Support Team for Central Camden PCN. MG is funded in part by NIHR Applied Research Collaboration NWC. TH received travel and accommodation in UK to facilitate a talk for Multiple Sclerosis Debating Society and an honorarium payment related to the Acute and General Medicine Conference. GL is Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo; no fees are received personally. HM has received funding from AstraZeneca related to use of monoclonal antibodies in acute COVID-19 treatment, from Millfield Medical in relation to the development of a new CPAP machine for use in hypoxic ventilatory failure, and from Axcella Health Inc about possible new therapeutics. He has delivered paid lectures to legal groups about Long Covid, received support to attend meetings as part of consultancy for AstraZeneca, participated on advisory boards for AstraZeneca and Axcella Health. HM has been involved as Chair, UK National Covid Critical Care Committee; Trustee, UK Intensive Care Society and has stock options with Millfield Medical Ltd. WDS has received research grants from AstraZeneca, Bayer, Novartis, Novo Nordisk and Takeda, and speaker and/or advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Mundi-Pharma, Napp, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier and Takeda. DJC has received investigator-initiated research funding, conference and/or consultancy fees from NovoNordisk, Astra Zeneca and Ipsen. CW

has had recent involvement with nine UK-based grants, has contributed to five advisory boards and been involved with six project groups or committees in a leadership or fiduciary capacity. CW has been involved with six NIHR collaborations/projects, of which STIMULATE-ICP is one. NW is a member of NIHR HTA Programme Funding Committee (commissioned research). DGW is supported by an NIHR Advanced Fellowship; University of Liverpool receives an NHS hourly rate for his consultancy work with an NHS Advancing Quality Alliance programme; he has no conflicts of interest. All other authors have no conflicts of interest to report.

### Data availability statement

This article describes a study protocol and as such does not report data. The data availability policy is therefore not applicable to this article.

#### 1 Abstract

2

#### 3 Introduction

4 As mortality rates from COVID-19 disease fall, the high prevalence of long-term sequelae 5 (Long COVID) is becoming increasingly widespread, challenging healthcare systems 6 globally. Traditional pathways of care for Long Term Conditions (LTCs) have tended to be 7 managed by disease-specific specialties, an approach that has been ineffective in delivering 8 care for patients with multi-morbidity. The multi-system nature of Long COVID and its 9 impact on physical and psychological health demands a more effective model of holistic, 10 integrated care. The evolution of integrated care systems (ICSs) in the UK presents an 11 important opportunity to explore areas of mutual benefit to LTC, multi-morbidity and Long 12 COVID care. There may be benefits in comparing and contrasting ICPs for Long COVID 13 with ICPs for other LTCs.

### 14 Methods and analysis

15 This study aims to evaluate health services requirements for ICPs for Long COVID and their 16 applicability to other LTCs including multi-morbidity and the overlap with medically not yet 17 explained symptoms (MNYES). The study will follow a Delphi design and involve an expert 18 panel of stakeholders including people with lived experience, as well as clinicians with 19 expertise in Long COVID and other LTCs. Study processes will include expert panel and 20 moderator panel meetings, surveys, and interviews. The Delphi process is part of the overall 21 STIMULATE-ICP programme, aimed at improving integrated care for people with Long 22 COVID.

# 23 Ethics and dissemination

Ethical approval for this Delphi study has been obtained (Research Governance Board of the
University of York) as have approvals for the other STIMULATE-ICP studies. Study

- 26 outcomes are likely to inform policy for ICPs across LTCs. Results will be disseminated
- 27 through scientific publication, conference presentation and communications with patients and
- 28 stakeholders involved in care of other LTCs and Long COVID.

### 29 Registration

- 30 Researchregistry: https://www.researchregistry.com/browse-the-
- 31 registry#home/registrationdetails/6246bfeeeaaed6001f08dadc/.

### 32 Introduction

33 Despite major reductions in acute COVID-19 hospitalisation and mortality,[1] the persistence 34 of symptoms over one year later is notable in the 45% of the 1.5 million individuals who had 35 symptoms four weeks post-COVID in the UK.[2-4] Unlike some long-term conditions 36 (LTCs), individuals with Long COVID (i.e. those with post-COVID symptoms >12 weeks) 37 may still fully recover. However, new care pathways for Long COVID attempt to manage it 38 akin to a LTC, given the increasing recognition of chronic symptoms.[4, 5] 39 Care pathways for LTCs have tended to be disease- or specialty-specific, an approach which 40 fails to accommodate the heterogeneity of symptoms occurring in Long COVID. ICPs are 41 structured, multi-disciplinary plans of the whole care pathway from primary care to specialist 42 services and rehabilitation services, which may be better suited to Long COVID.[6-8] They 43 offer coordination of investigation, treatment and rehabilitation, as well as opportunities for 44 real-time iterative improvements in service design and delivery, quality and access to care, patient experience and satisfaction, while reducing complications and non-elective admission 45 46 rates.[9-11] Evolution of integrated care systems (ICSs) in the UK provide opportunities to 47 improve care across LTCs, multi-morbidity or multiple health conditions,[12] and Long 48 COVID. 49 Long COVID encompasses a broad array of symptoms and symptom clusters. It is unlikely to 50 reflect a single condition or pathology; rather it reflects a multi-faceted condition with 51 numerous contributory factors: some identifiable, and others not yet understood.[13] 52 Trajectory and recovery after SARS-CoV-2 infection are poorly defined and there is overlap

53 with medically not yet explained symptoms (MNYES), referring to symptoms which do not

54 represent a known medical condition, yet contribute significantly to lesser quality of life and

55 treatment need.[14] Multi-organ complications,[13, 15-18] including neuropsychiatric

56 sequelae (up to 20%), are well-documented.[19-24]

57 Table 1 shows current models that can potentially be applied to Long COVID ICPs. 58 Depending on setting, expectations and provisions regarding treatment may differ. It can be 59 argued that some current models for managing LTCs require improvement[25] as they cannot 60 cover the whole range of patient presentations; episodic care is not appropriate for 61 unpredictable exacerbating conditions, for example heart failure and COPD.[26, 27] An effort 62 should be made to explore how to achieve integrated care from the perspective of individual 63 conditions, but also from the perspective of how health services and settings can inform each 64 other, and work together, to deliver optimal care for LTCs. The current pandemic and effort 65 to set up Long COVID clinics[28] offers a unique opportunity to explore this from the 66 perspective of Long COVID, and then to translate back to ICPs for other LTCs. For example, 67 model 2 could also be based in primary care with better integration of GPs, primary care 68 nurses and therapists. Model 3 could be more of a shared care arrangement between primary 69 and secondary care with two-way data flow between these two sectors. In other words, one of 70 the solutions for Long COVID care could be better working arrangements between 71 community services, primary care and specialty care and ICSs might offer the perfect space 72 for this in England. 73

- 74
- 75
- 76
- 77

78

# **Table 1: Potential models for ICPs managing recovery in Long COVID and other LTCs**

Model	Example condition(s)	Recovery time	Managed by	Approach
Model 1	Community Acquired Pneumonia (CAP)	This may take 6 months	Primary care teams and community	Currently there is no well-developed integrated care pathway but
		to fully recover in terms	General Practitioners (GPs). There is a	there could be a chance to identify how to identify CAP follow up
		of fatigue (NICE	NHS CAP CQUIN aiming to support	better based upon Long COVID care experiences.
		guideline)[29]	discharge from the hospital and safe	They support the patient through their recovery with the length of
			follow up of these patients.	complete recovery and the ramifications for work often
			Follow up imaging is usually arranged by	underestimated.
			secondary care.	
Model 2	Post myocardial infarction, significant	Taking a medium	Multi-disciplinary team (MDT) driven	Rehabilitation approach, personalised to the individual including a
	musculoskeletal injury	course to resolution,	and mostly provided in rehabilitation	biopsychosocial approach to care, with physiotherapy and medical
		e.g., 1-2 years.	clinics.	attention to address anxiety and depressive symptoms
Model 3	A chronic disease like type 2 diabetes or	It is managed but often	Usually managed in primary or	Escalation of a small proportion with complex needs being
	stroke	recovery is not	community care, by GPs and diabetes	managed in a specialist setting[30]
		complete.	nurses, or in the hospital setting.	
Model 4	COPD Rheumatoid Arthritis	A chronic condition that	Limited care provision, mostly based in	COPD is a condition that shares breathlessness as an important
		may have high	primary care with exacerbations	symptom with Long COVID, where pulmonary rehabilitation is a
		disability with tendency	increasingly managed in hospital in later	key evidence based treatment and supporting self-management is a
		for relapses/	stages. Growing emphasis on need to	key goal. Impact on function, breathlessness and psychological
		exacerbations.	improve community diagnostics and	wellbeing as in Long COVID. Both conditions have a relapsing

			where pulmonary rehabilitation is a key	course of symptoms that may benefit from prompt intervention.
			evidence-based treatment.	There is growing emphasis on the need to improve community
				diagnostics.
Model 5	Comorbid mental disorders and other	These are in general	Mental disorders have case management,	There are pilot playgrounds for dedicated respiratory clinics for
	LTC.	chronic conditions with	crisis teams, psychiatry follow up, but	patients with mental illness across the country.
		high disability.	they do not identify physical health needs	
	For example, COPD in patients with		of their patients, such as respiratory	Similar pilots exist for diabetes and depression - either community-
	mental disorders, often related to	There is an unmet	issues. And clinics for somatic conditions	based or hospital-based.
	smoking.	clinical need here.	can have short-term treatments available	
	Or, depression in diabetes patients.		for psychological treatments but there is a	
			lack of available long-term integrated	
			treatment.	
Model 6	Encompassing multi-morbidity (i.e. more	The perceived burden of	No current consistent pathway of care	These patients are highly likely to benefit from an ICP. This would
	than two LTCs) as well as a spectrum of	disease is high.	exists. Consultation, collaborative care	be best served with a flag up system approach which is for people
	symptoms that do not fit into a usual	These are conditions	and decision aids supporting health care	who don't quite meet full diagnostic criteria in one condition but
	pattern for diagnosis of a single disease	requiring a multisystem	providers to provide ICP would be	almost meet it in many conditions. This would be labelled as
	i.e. MNYES,[14] or both, crossing the	approach.	possibilities to link primary, community	MNYES but disease burden is high and there is a need to integrate
	mental health and physical health divide.		and specialist health care settings	physical and psychological health care provision.

80

Acronyms: Community Acquired Pneumonia (CAP), National Institute for Health and Care Excellence (NICE), General Practitioner (GP), National Health Service (NHS), Commissioning for Quality and Innovation

81 (CQUIN), Multi-disciplinary team (MDT), Chronic Obstructive Pulmonary Disease (COPD), Long term condition (LTC), Integrated care pathway (ICP), Medically not yet explained symptoms (MNYES).

82	Even in well-defined entities such as community acquired pneumonia (CAP), symptoms such
83	as fatigue[31] may take up to six months to resolve, even in young, physically fit people,
84	fuelling fears that their symptoms will not abate, which may be biologically, psychologically,
85	or socially driven, or depend on treatment setting. Learning from other LTCs, optimal Long
86	COVID management may require a biopsychosocial model, rather than consideration of these
87	components separately.[32]
88	
89	Research question
90	What are effective ICPs for individuals with Long COVID and how can they be transferred to
91	other LTCs including mental disorders, multi-morbidity and the interface between known
92	medical disorders and MNYES[14] as well as newly developed conditions?
93	
94	Materials and Methods
95	Aims
96	In a Delphi study using a biopsychosocial approach, we will investigate:
96 97	<ul><li>In a Delphi study using a biopsychosocial approach, we will investigate:</li><li>1. (a) Key enabling elements for effective ICPs for individuals with long COVID, based on</li></ul>
97	1. (a) Key enabling elements for effective ICPs for individuals with long COVID, based on
97 98	<ol> <li>(a) Key enabling elements for effective ICPs for individuals with long COVID, based on user experience, and (b) Strengths of existing ICPs for other LTCs.</li> </ol>
97 98 99	<ol> <li>(a) Key enabling elements for effective ICPs for individuals with long COVID, based on user experience, and (b) Strengths of existing ICPs for other LTCs.</li> <li>Which (part of an) ICP model for Long COVID can be transferred to other LTCs for which</li> </ol>
97 98 99 100	<ol> <li>(a) Key enabling elements for effective ICPs for individuals with long COVID, based on user experience, and (b) Strengths of existing ICPs for other LTCs.</li> <li>Which (part of an) ICP model for Long COVID can be transferred to other LTCs for which care pathways were not yet developed sufficiently, and how.</li> </ol>
97 98 99 100 101	<ol> <li>(a) Key enabling elements for effective ICPs for individuals with long COVID, based on user experience, and (b) Strengths of existing ICPs for other LTCs.</li> <li>Which (part of an) ICP model for Long COVID can be transferred to other LTCs for which care pathways were not yet developed sufficiently, and how.</li> </ol>
97 98 99 100 101 102	<ol> <li>(a) Key enabling elements for effective ICPs for individuals with long COVID, based on user experience, and (b) Strengths of existing ICPs for other LTCs.</li> <li>Which (part of an) ICP model for Long COVID can be transferred to other LTCs for which care pathways were not yet developed sufficiently, and how.</li> <li>Variations in uptake and adherence to treatment in Long COVID and LTCs.</li> </ol>

106 Transform Existing Integrated Care Pathways).[33] (**Figure 1**)

107	
108	[ Figure 1]
109	
110	STIMULATE-ICP is funded by the National Institute for Health Research (NIHR: COV-LT2-
111	0043)[34] and combines clinical epidemiological studies, a complex randomised trial exploring
112	the benefit of an ICP for Long COVID (IRAS: 1004698), and mixed methods studies exploring
113	inequalities of care and transferability of the ICP to other LTCs (IRAS: 303958).
114	
115	The STIMULATE-ICP-DELPHI study will follow a Delphi process to establish consensus
116	agreement on statements relating to ICPs and the transferability of ICP models between Long
117	COVID and LTCs. The Delphi approach is a structured method for collecting opinions of
118	experts concerning a subject of their expertise, reaching consensus over a number of
119	rounds.[35] Since its development in the 1950s[36] a commonly used variation of the Delphi
120	method is the estimate-talk-estimate Delphi method that combines assembling of expert
121	opinions on an anonymous basis during surveys with open exchange during workshops
122	moderated by a facilitator.[37] This Delphi method will be followed in this study,[38] aiming
123	for stepwise consensus through three rounds of expert panel meetings involving exploration,
124	prioritization, and as a final step attaining consensus(Figure 2).
125	
126	[ Figure 2]
127	
128	The meetings will be interwoven by two online surveys, with addition of qualitative
129	interviews. After a "knowledge check", an information package based on the survey and
130	interview outcomes will be provided to the panel. The expert panel will then discuss
131	outcomes and provide policy recommendations in a final meeting.[39]

1	27	
1	32	

133	This study will depart from the theoretical framework of Goldberg and Huxley's filter-model
134	of access to care[40, 41] that describes four filters; three of which a patient has to navigate to
135	enter a primary care treatment pathway, and a fourth to access specialist treatment. This
136	model was originally developed for access to care for mental disorders, but it would be a
137	good fit for exploring barriers and facilitators to entering Long COVID services and other
138	LTCs not only for psychological symptoms but for physical symptoms as well. This extended
139	model spans multiple healthcare challenges and extends the existing inequalities in health
140	such as limited access to healthcare, incomplete pathways across community and hospital
141	care, inadequate research translation to practice, and overall insufficient healthcare resources
142	(Figure 3).
143	[Figure 3]
144	
145	People with Long COVID and those with LTCs frequently present to healthcare services with
146	multiple symptoms.[42-44] Therefore, this study will take account of competing demands to
147	determine how people seeking support prioritise their symptoms when seeking help, and how
148	healthcare providers deal with multiple symptoms reported when making decisions about
149	appropriate care.[45, 46]
150	
151	Study management
152	This work will involve a research team (n=3), a moderator panel (MP) (n=3) and an expert
153	panel (EP)(n=25). The research team will prepare, distribute and analyse all information for
154	the project. The MP will meet regularly, providing advice and guidance to the research team
155	to ensure scientific quality. The EP will include people with expertise in academic and
156	clinical research in addition to lived experience of Long COVID, other LTCs such as

157 cardiovascular disorders, type 2 diabetes, mental disorders and MNYES, or multi-morbidity;158 5 of each group with a minimum of 25.

159

EP members will be selected by the MP building on suggestions from the Royal College of
General Practitioners and national charities following a snowballing method. Patients with
illness experience of Long COVID and other LTCs will be identified by clinics, medical
trusts, patient networks and charities following a snowballing method. As part of the
invitation process, the research team will inform prospective EP members about their role
within the study. The EP will provide information and advice relating to their experiences of
living with, or supporting people with Long COVID or LTCs.

# 168 Sample size, participant characteristics, inclusion and exclusion criteria

169 Recruitment for Survey 1 will involve collecting quantitative and qualitative data from two 170 purposive samples selected from community, primary care, and specialist settings. Sampling 171 will seek to achieve sufficient numbers (minimum of N = 50 per group) in order to have a 172 representative sample. Sample 1: patients/carers and clinicians with experience of Long 173 COVID and other post COVID morbidity across England. Sample 2: patients/carers and 174 clinicians involved in other LTCs. Participants in both samples will be recruited via the study 175 website, with support from relevant online forums, associations and charities. As personalised 176 care is now a specific NHS workstream which is intended to touch on all the LTC pathways, 177 we will seek the opinion of ICS stakeholders (commissioners and those involved in the 178 clinical networks) as to how personalised care should be delivered.[47-52] 179

180 The selection of interviewees for the qualitative study will be nested in the surveys.

181 Participants from Survey 1, willing and able to provide informed consent, will be invited

182 (using a separate survey link) to express interest in participating in an interview to discuss 183 their experiences of healthcare relating to Long COVID and/or LTCs. Using details from the 184 expression of interest form, the research team will select a purposive sample of people 185 (minimum N=10-15) to interview. Within those volunteers, a maximum variation approach to 186 participant selection will be adopted to ensure a wide range of experiences are reflected 187 (accounting for experience of Long COVID and/or LTC(s), patient/clinician). Sampling will 188 stop once saturation is reached. Both patients and clinicians will be interviewed as to how 189 they deal with multi-morbidity or multiple symptoms and competing demands when 190 accessing or providing healthcare, and the barriers and facilitators to providing or receiving 191 ICP.[53-60] 192 193 Data saturation 194 Interviews conducted for this research aim to supplement and provide context to the

statements made by Survey 1 participants. For each group of interview participants
(patients/clinicians with experience of Long COVID or LTCs), saturation will have been

197 achieved when interviews stop providing new topics/themes which relate to ICPs.

198

### 199 Patient and public involvement

200 The parent study STIMULATE-ICP has been enriched by robust patient and public

201 involvement (PPI) using multiple channels, including regular updates and webinars, surveys,

202 social media. The STIMULATE-ICP DELPHI study has been informed by existing

203 engagements with people with experience of Long COVID/ LTCs in research, and PPI co-

applicants who will contribute to methods and outputs. In addition, people with relevant

205 disease experience will be involved in the EP and will be involved in the selection of other

206 LTCs for comparison. Public and patients will be involved as stakeholders for this project,

increasing awareness with relevant groups and promoting research activities. PPI will be
involved in drafting the recommendations and their contributions through the EP and the
wider STIMULATE-ICP team will shape our ultimate policy recommendations and the
dissemination of this work. PPIE leads and co-applicants will contribute to the management
and conduct of Delphi and qualitative interviews, the analysis plan and dissemination of the
findings.

213

214 Study processes

215 Round 1

216 During the initial EP meeting, the scope of this work will be agreed. This work will focus on 217 adults (18 and over); outcomes will include confirming the list of relevant LTCs and those 218 considered out of scope. As an inclusive approach, a variety of LTCs including mental 219 disorders, multi-morbidity and the interface with MNYES will be considered. Fatigue, as a 220 symptom, will be in scope, myalgic encephalomyelitis or chronic fatigue syndrome 221 (ME/CFS) will be considered out of scope for this survey. Cognitive limitations will be in 222 scope, non-capacity will be out of scope for the survey. Following confirmation of the scope, 223 EP members will discuss and agree on questions to ask in Survey 1. The survey will include 224 questions about: 225 1) Demographic factors (age, gender, ethnicity), relevant disease experience as patient or 226 clinician, and clinical and work functioning profile of participants. 227 2) Experiences of Long COVID which prompted help-seeking with a focus on the process of

seeking treatment, referrals, treatment(s) offered and received and whether there were any
barriers or facilitators to that.

- 230 3) Challenges and advances for clinical care, knowledge gaps and policies, possible
- 231 improvements to services, transferability of care models to other conditions will be explored
- for Long COVID and for other LTC ICPs.
- 233

234 Survey 1

- 235 This will be an anonymous, online survey (using the Qualtrics[61] platform) to establish
- 236 demographic information and to explore the topics by open questions. Participants will also
- 237 be invited to give a first indication of what their priorities to improve integrated care would

238 be.

239

240 Round 1 Interviews

Qualitative semi-structured interviews will be used to examine the experience, and needs fortreatment, of people living with Long COVID and other LTCs.

243

244 Examples of good practice will also be sought. Interview topic guides will be developed with 245 guidance from the MP. Interviews will be offered over the telephone or a secure video-246 conferencing platform (zoom). Interviews are expected to last 40-50 minutes, but no longer than one hour, to reduce participant burden. With consent, they will be audio-recorded to 247 248 allow verbatim transcription.[62-64] Where respondents appear fatigued, they will be given 249 the option for the interview to take place over two time-periods, to have a family member 250 present, or to shorten the length of the interview. The researcher will stop the interview at any 251 point if participants indicate discomfort or distress.

252

253 *Round 2* 

254 The EP will use data from Survey 1 and the interviews to create a list of statements about

- 255 1) Current Long-COVID clinics and future recommendations.
- 256 2) Current care models for LTCs.
- 257 Statements are likely to relate to how symptoms impact on general and social functioning and
- 258 service use. Statements will also explore treatment and service need for people across
- 259 different disease / condition profiles, in order to inform the recommendation phase.
- 260
- 261
- 262 Survey 2
- 263 There will be a second anonymous online survey seeking to explore for which statements
- 264 consensus exists. Participants will review and respond to each of the statements using a 7-
- 265 point scale (1. Totally disagree, 7, Totally agree).
- 266
- 267 *Round 3*
- 268 In a final meeting, the expert panel will use the findings to finalise a series of consensus-
- based recommendations about optimal care models for Long COVID and how these can be
- applied to other LTCs. These recommendations will be shared with healthcare professionals,
- 271 policy makers and healthcare commissioners with the potential to influence future care.
- 272

### 273 Data analysis and outcomes

274 Data analysis will provide descriptive statistics to outline the demographic characteristics of

the two samples. Item response frequencies provide information about the current services

- 276 offered. Open-ended questions will capture individual experiences of services and
- suggestions for future improvements. Responses will be organised into themes, with the
- 278 research team adopting a pragmatic approach to provide feedback for the second expert panel
- 279 meeting.

280

281 Thematic analysis will be conducted on data transcripts for round 1 interviews.[65] Theme 282 development will be derived deductively from the topic guide. However, we will also allow 283 for inductive theme development and will actively seek to identify new themes or topics 284 within our data.[66] Following initial deductive and inductive coding, analysis will be set in 285 the context of relevant theoretical concepts from the experience of chronic illness, such as, 286 for example, the adapted Goldberg and Huxley's filter model; [40] competing demands in 287 primary care; [46] biographical disruption; [67] and illness careers. [68] Emergent patterns and 288 early analysis will be discussed at regular research and moderator panel meetings for 289 comment. Data from Survey 1 and Interviews will be combined and presented to the EP for 290 consideration during round 2 of this study.

291

Data analysis will collate responses to Survey 2. Then consensus of opinion about each statement will be assessed using interquartile deviations (IQD). For this calculation, at least 50% of individuals will have responded using the same category. IQD  $\leq$  1 is considered to indicate consensus. Findings from survey 2 will be combined with an information pack based upon input from other STIMULATE-ICP sub studies as lined out in Figure 1, and shared with the EP members.

298

### 299 Data management plan

This study will produce online survey data and qualitative interview data. Online surveys will be anonymous and therefore a survey ID code will be created for participants (for example, S146 would be the code given to Survey 1 participant number 46). Data will be downloaded from Qualtrics to Microsoft Excel. Qualitative interview data will be audio recorded via Zoom (for virtual interviews or telephone interviews). Participant ID codes will

305	be provided to all participants (for example, DI07 would be the code given to Delphi
306	Interview participant number 7). A password-protected Microsoft Excel file will be used to
307	track the status of data preparation for each interview; this document will contain participant
308	names and ID codes. Audio recording will be transcribed verbatim into Microsoft Word
309	documents. Transcripts will then be anonymised ready for analysis.
310	
311	All data will be stored electronically on the University of York secure server with access
312	restricted to the research team involved with this project. Analysis will be conducted in
313	Microsoft Excel, SPSS and NVivo. Anonymous data (such as Survey 1 original responses)
314	will be shared with MP and EP members to enable discussions and decisions about the
315	organisation of data and the development of statements.
316	
317	Ethics
318	This Delphi study was reviewed and approved by the University of York Department of
319	Health Sciences Research Governance Committee in December 2021
320	(HSRGC/2021/478/A:STIMULATE).
321	
322	Informed consent
323	SURVEY
324	Regarding the survey, following the presentation of participant information, consent for
325	anonymous data to be collected, analysed and disseminated as part of this project will be
326	required before survey questions are displayed for Surveys 1 and 2.
327	INTERVIEW
328	Regarding the interview, a separate survey link will be embedded at the end of Survey 1 to
329	enable participants to express an interest in participating in a subsequent qualitative interview

330 without linkage to their survey answers. All individuals who express an interest in being 331 interviewed will be contacted to confirm whether they have been selected to contribute to the 332 interviews. Individuals who are selected for interview will then receive full interview study 333 information and will be required to provide consent if they wish to participate in an interview. 334 Data handling 335 The study is compliant with the requirements of General Data Protection Regulation 336 (2016/679) and the UK Data Protection Act (2018). All investigators involved in the study 337 will comply with the requirements of the General Data Protection Regulation (2016/679) with

regards to the collection, storage, processing and disclosure of personal information, and will

339 uphold the Act's core principles. For this STIMULATE-ICP Delphi sub-study, survey data

340 will be downloaded and stored/archived at the University of York. All interviews will be

341 recorded. Interview data will be transcribed and coded by JS and will be identified and

342 stored/archived at the University of York. Information provided to survey and interview

343 participants will outline their right to withdraw at any point during this research. Data

344 collected up to the point of withdrawal will be used unless there is an expressed request for

345 withdrawal of all data.

346 Safety considerations

There are not considered to be any safety concerns for participants involved with this project. 347 348 EP and MP members will be informed of the project aims, the focus of their role and the 349 project timescales prior to joining the study. These are voluntary roles and individuals can 350 withdraw from the study at any time. Likewise, Survey participants' data will be shared 351 anonymously with basic demographic details being collected to enable researchers to 352 describe the sample. Survey participants will be able to ask questions to the research team, provide consent and withdraw at any point. Interview participants will provide contact 353 354 details to the research team to enable interviews to be organised and conducted. Transcribed

- 355 data will be anonymised, and interview participants can stop or pause interviews at any point
- 356 should they wish to. All data collected will be online, virtually or using the telephone to
- 357 minimise any burden for participants. The anticipated time to complete each research activity
- 358 will be shared with potential participants to enable them to make informed decisions about
- 359 whether to participate in each element of the study.
- 360
- 361 Status and study timeline
- 362 Jan-Feb 2022 Recruitment of Expert Panel members
- 363 March 2022 Initial Expert Panel meeting
- 364 April 2022 Survey 1 launched online
- 365 May 2022 Interviews started
- 366 June 2022 Survey 1 closed
- 367 July 2022 Interviews completed, Survey 1 data cleaning and analysis
- 368 August 2022 Survey 1 data analysis, Interview data transcription, small groups of Expert
- 369 Panel members discuss preliminary organisation of data from Survey 1
- 370 September 2022 Second Expert panel meeting, Interview data analysis
- 371 October 2022 Launch of Survey 2 online, Interview data analysis
- 372 November 2022 Interview data analysis
- 373 December 2022 Survey 2 closed, Interview data analysis
- 374 January 2023 Survey 2 data cleaning and analysis
- 375 Feb/March 2023 Final Expert Panel meeting
- 376 March 2023 Key recommendations finalised and disseminated
- 377
- 378 Discussion
- 379 Dissemination

- 380 We will publish the findings from this Delphi study in peer reviewed journals and will
- 381 present the findings during conferences. Table 2 provides an overview of the proposed
- deliverables for stakeholders during the study.

### 383 Table 2 Dissemination to stakeholders

Early deliverables Early read out and contact with stakeholders (NHS England, the Royal				
	College of GPs, AHSNs, other Royal Colleges, RCP, RCPsych, patient groups			
	and NICE)			
What should integrated	care look like? What should	be integrated for Long COVID, o	ther LTCs and	
multimorbidity?				
How can ICPs integrate	primary and specialty health	care, as well as somatic and men	tal health care?	
Patient and clinician exp	periences in ICPs and variety	in Long COVID and other LTCs	regarding funding and	
structure of their care pa	thways.			
Inform care pathways for	or other LTCs that are unhear	d or under-served.		
What are facilitators and	l barriers to integrated care p	athways?		
Final deliverable	Final deliverable Contact with stakeholders (NHS England, the Royal College of GPs, AHSNs,			
	other Royal Colleges, RCP, RCPsych, patient groups and NICE)			
Outputs	Webinar contact with	Report with summary of	Policy	
	stakeholders	findings for stakeholders	recommendations	
Novel models of provisi	on across sectors, addressing	biological, psychological and so	cial components as a	
matter of routine, new n	nulti-disciplinary groups in s	ettings such as primary care.		

384

385

# 386 Conclusions

387 The pandemic and the legacy of Long COVID will alter the landscape of the UK NHS

- 388 forever, and possibly health care systems in other countries as well. This Delphi study can
- 389 support a novel way of developing integrated models of care. It will inform the beginning of

- 390 a change in NHS integrated care systems across diseases and the primary and specialty health
- 391 care divide, while putting the patient first.

# 392 Authors' Contributions

393 Conceptualisation and methodology: CFC, JS, GA, EA, MG, AB, STIMULATE-ICP team.

- 394 Funding acquisition: all authors. Ethics: CFC, AB, PM. Project administration: CFC. Original
- 395 manuscript drafting and preparation: CFC, JS. Review and editing of manuscript: all authors.
- 396 Patient and public involvement: LH, EA. All authors approved the final version of the article.
- 397

#### 398 Acknowledgements

399 This paper has been published on behalf of the STIMULATE-ICP Consortium: Professor

400 Amitava Banerjee (Chief Investigator), Professor Paula Lorgelly, Professor Elizabeth

401 Murray, Dr Hakim-Moulay Dehbi, Professor Hugh Montgomery, Dr Yi Mu, Sarah Clegg, Dr

402 Mel Ramasawmy–University College London; Dr Melissa Heightman (Co-Chief

403 Investigator), Dr Toby Hillman, Dr Emma Wall, Dr Michael Zandi—University College

404 London Hospitals NHS Foundation Trust; Professor Dame Caroline Watkins, Denise

405 Forshaw, Dr Gordon Prescott–University of Central Lancashire; Dr Gail Allsopp–

406 Derbyshire NHS Foundation Trust/Royal College of General Practitioners; Professor Mark

407 Gabbay, Professor Gregory Lip, Professor Dan Cuthbertson, Dr Dan Wootton, Professor

408 Nefyn Williams—University of Liverpool; Dr Michael Crooks—University of Hull; Dr

409 Angela Green—Hull University Teaching Hospitals Trust; Professor Christina van der Feltz-

410 Cornelis, Dr Jennifer Sweetman, Dr Han-I Wang, Natalie Smith—University of York;

411 Professor Kamlesh Khunti—University of Leicester; Dr David Strain—University of Exeter;

412 Dr Emily Attree, Jasmine Hayer, Rachel Hext, Lyth Hishmeh, Kim Horstmanshof, Mag

413 Leahy, Antony Loveless, Clare Loveless, Rita Mallinson Cookson, Andrew Williams, Rachel

- 414 Williams–PPI Representatives; Dr Nisreen Alwan, Dr Donna Clutterbuck—University of
- 415 Southampton; Dr Marija Pantelic—University of Sussex; Chris Robson—Living With
- 416 COVID Recovery; Professor Sir Mike Brady, Dr Rajarshi Banerjee, Dr Cat Kelly-

- 417 Perspectum. An up-to-date version of Consortium members can be
- 418 found: https://www.stimulate-icp.org/team. STIMULATE-ICP can be contacted
- 419 at: info@stimulate-icp.org Papiya Mazumdar contributed to obtaining ethics approval.
- 420

### 421 **References**

- 422 1. Gerotziafas GT, Catalano M, Theodorou Y, Van Dreden P, Marechal V, Spyropoulos AC, et al.
- 423 The COVID-19 pandemic and the need for an integrated and equitable approach: an international
- 424 expert consensus paper. Thrombosis and Haemostasis. 2021;121(08):992-1007.
- 425 2. The King's Fund. Long-term conditions and multi-morbidity 2022 [Available from:
- 426 https://www.kingsfund.org.uk/projects/time-think-differently/trends-disease-and-disability-long-
- 427 term-conditions-multi-
- 428 morbidity#:~:text=Long%2Dterm%20conditions%20or%20chronic,pulmonary%20disease%2C%2
  429 0arthritis%20and%20hypertension.
- 430 3. NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19 2022 [Available
- 431 from: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-
- 432 longterm-effects-of-covid19-pdf-51035515742.
- 433 4. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi
- 434 consensus, 6 October 2021 2021 [Available from: https://www.who.int/publications/i/item/WHO-
- 435 2019-nCoV-Post\_COVID-19\_condition-Clinical\_case\_definition-2021.1.
- 436 5. NHS England, NHS Improvement. National Guidance for post-COVID syndrome assessment
- 437 clinics: NHS England and NHS Improvement; 2021 [updated 26.04.2021. Version 2:[Available
- 438 from: https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C1248-
- 439 national-guidance-post-covid-syndrome-assessment-clinics-v2.pdf.
- 440 6. Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical,
- 441 cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK
- 442 multicentre, prospective cohort study. The Lancet Respiratory Medicine. 2021;9(11):1275-87.

- 443 7. ONS. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 3
- 444 March 2022 2022 [Available from:
- 445 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseas
- 446 es/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3march2
- 447 022.
- 448 8. Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. British Medical
  449 Journal. 1998;316(7125):133-7.
- 450 9. Plishka CT, Rotter T, Penz ED, Hansia MR, Fraser S-KA, Marciniuk DD, et al. Effects of clinical
- 451 pathways for COPD on patient, professional, and systems outcomes: a systematic review. Chest.
- 452 2019;156(5):864-77.
- 453 10.Baxter S, Johnson M, Chambers D, Sutton A, Goyder E, Booth A. Understanding new models of
- 454 integrated care in developed countries: a systematic review. Health Services and Delivery
  455 Research. 2018;6(29).
- 456 11.Mitchell GK, Burridge L, Zhang J, Donald M, Scott IA, Dart J, et al. Systematic review of
- 457 integrated models of health care delivered at the primary–secondary interface: how effective is it
- 458 and what determines effectiveness? Australian Journal of Primary Health. 2015;21(4):391-408.
- 459 12. Whitty CJ, MacEwen C, Goddard A, Alderson D, Marshall M, Calderwood C, et al. Rising to the
- 460 challenge of multimorbidity. British Medical Journal; 2020; 368: 16964.
- 461 13.Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19
- 462 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199(2):113-9.
- 463 14.James Lind Alliance. Medically Not Yet Explained Symptoms 2022 [Available from:
- 464 https://www.jla.nihr.ac.uk/priority-setting-partnerships/medically-not-yet-explained-symptoms/.
- 465 15.Stefano GB. Historical insight into infections and disorders associated with neurological and
- 466 psychiatric sequelae similar to long COVID. Medical Science Monitor. 2021;27:e931447-1.

- 467 16.Miskowiak K, Johnsen S, Sattler S, Nielsen S, Kunalan K, Rungby J, et al. Cognitive impairments
- 468 four months after COVID-19 hospital discharge: pattern, severity and association with illness
- 469 variables. European Neuropsychopharmacology. 2021;46:39-48.
- 470 17. Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain
- 471 fog and chemofog: Luteolin to the rescue. Biofactors. 2021;47(2):232-41.
- 472 18.Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic
- 473 symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Annals of
- 474 Clinical and Translational Neurology. 2021;8(5):1073-85.
- 475 19. Varatharaj A, Thomas N, Ellul MA, Davies NW, Pollak TA, Tenorio EL, et al. Neurological and
- 476 neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. The
- 477 Lancet Psychiatry. 2020;7(10):875-82.
- 20.Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of
  COVID-19. The Lancet Neurology. 2020;19(9):767-83.
- 480 21. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and
- 481 psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The
- 482 Lancet Psychiatry. 2021;8(2):130-40.
- 483 22.Khan S, Gomes J. Neuropathogenesis of SARS-CoV-2 infection. Elife. 2020;9:e59136.
- 484 23.Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, et al. Frequent neurocognitive
- deficits after recovery from mild COVID-19. Brain Communications. 2020;2(2):fcaa205.
- 486 24.Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-
- 487 sectional study of persisting symptoms, biomarker and imaging abnormalities following
- 488 hospitalisation for COVID-19. Thorax. 2021;76(4):396-8.
- 489 25.Royal College of Physicians. Outpatients: the future adding value through sustainability. London:
  490 RCP; 2018.

- 491 26.Martínez-González NA, Berchtold P, Ullman K, Busato A, Egger M. Integrated care programmes
- 492 for adults with chronic conditions: a meta-review. International Journal for Quality in Health Care.
- 493 2014;26(5):561-70.
- 494 27.Goodwin N, Smith J, Davies A, Perry C, Rosen R, Dixon A, et al. Integrated care for patients and
- 495 populations: improving outcomes by working together. London: King's Fund. 2012.
- 496 28.NHS. Long COVID patients to get help at more than 60 clinics 2020 [Available from:
- 497 https://www.england.nhs.uk/2020/12/long-covid-patients-to-get-help-at-more-than-60-clinics/.
- 498 29.NICE. Scenario: Community-acquired pneumonia 2021 [Available from:
- 499 https://cks.nice.org.uk/topics/chest-infections-adult/management/community-acquired-
- 500 pneumonia/.
- 501 30.Seidu S, Davies M, Farooqi A, Khunti K. Integrated primary care: is this the solution to the
- 502 diabetes epidemic? Diabetic Medicine. 2017; 34(6):748-750.
- 503 31.Wootton DG, Dickinson L, Pertinez H, Eneje O, Keogan L, Macfarlane L, et al. A longitudinal
- 504 modelling study estimates acute symptoms of community acquired pneumonia recover to baseline
- 505 by 10 days. European Respiratory Journal. 2017;49(6).
- 506 32.Engel GL. The need for a new medical model: a challenge for biomedicine. Science.
- 507 1977;196(4286):129-36.
- 508 33.STIMULATE-ICP. STIMULATE-ICP 2022 [Available from: https://www.stimulate-icp.org/.
- 509 34.NIHR. £19.6 million awarded to new research studies to help diagnose and treat long COVID
- 510 2021 [Available from: https://www.nihr.ac.uk/news/196-million-awarded-to-new-research-studies-
- 511 to-help-diagnose-and-treat-long-covid/28205.
- 512 35.Adler M, Ziglio E. Gazing into the oracle: The Delphi method and its application to social policy
- 513 and public health: Jessica Kingsley Publishers; 1996.
- 514 36.Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts.
- 515 Management Science. 1963;9(3):458-67.

- 516 37.Wykes T, Haro JM, Belli SR, Obradors-Tarragó C, Arango C, Ayuso-Mateos JL, et al. Mental
- 517 health research priorities for Europe. The Lancet Psychiatry. 2015;2(11):1036-42.
- 518 38.Rowe G, Wright G. Expert opinions in forecasting: the role of the Delphi technique. Principles of
- 519 Forecasting: Springer; 2001. p. 125-44.
- 520 39.de Meyrick J. The Delphi method and health research. Health Education. 2003.
- 521 40.Goldberg D, Huxley P. Mental illness in the community: the pathway to psychiatric care London.
- 522 New York, Tavistock. 1980.
- 523 41.Simon GE. Improving the filter between primary and secondary care for mental disorders. World
- 524 Psychiatry. 2003;2(3):158.
- 525 42.Scordo KA, Richmond MM, Munro N. Post–COVID-19 syndrome: theoretical basis,
- identification, and management. AACN Advanced Critical Care. 2021;32(2):188-94.
- 527 43.Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado
- 528 ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-
- bospitalized COVID-19 survivors: A systematic review and meta-analysis. European Journal of
- 530 Internal Medicine. 2021;92:55-70.
- 531 44.Menchetti M, Murri MB, Bertakis K, Bortolotti B, Berardi D. Recognition and treatment of
- 532 depression in primary care: effect of patients' presentation and frequency of consultation. Journal
- 533 of Psychosomatic Research. 2009;66(4):335-41.
- 45.Nutting PA, Rost K, Dickinson M, Werner JJ, Dickinson P, Smith JL, et al. Barriers to initiating
- 535 depression treatment in primary care practice. Journal of General Internal Medicine.
- 536 2002;17(2):103-11.
- 46.Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of
- 538 clinical preventive services. Journal of Family Practice. 1994;38(2):166-74.
- 539 47.NHS England. Long COVID: the NHS plan for 2021/22 2021 [Available from:
- 540 https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/06/C1312-long-covid-
- 541 plan-june-2021.pdf.

STIMULATE-ICP Delphi (Symptoms, Trajectory, Inequalities and Management: **Understanding Long-COVID to Address and Transform Existing Integrated Care** Pathways): Delphi Study Protocol.

- 542 48.NHS. The NHS Long Term Plan 2019 [Available from: https://www.longtermplan.nhs.uk/wp-
- 543 content/uploads/2019/01/nhs-long-term-plan-june-2019.pdf.
- 544 49.NHS. NHS England's work on stroke [Available from:
- 545 https://www.england.nhs.uk/ourwork/clinical-policy/stroke/.
- 546 50.NHS. Long term conditions 2022 [Available from: https://www.england.nhs.uk/ourwork/clinical-
- 547 policy/ltc/.
- 51.NHS. Cardiovascular disease (CVD) [Available from: 548
- 549 https://www.england.nhs.uk/ourwork/clinical-policy/cvd/.
- 550 52.NHS. Respiratory disease [Available from: https://www.england.nhs.uk/ourwork/clinical-
- 551 policy/respiratory-disease/.
- 552 53.EQ-5D. EQ-5D-5L User Guide, 2019 2019 [Available from: https://euroqol.org/publications/user-
- 553 guides.
- 554 54. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure.

555 Journal of General Internal Medicine. 2001;16(9):606-13.

- 556 55.Lam RW, Lamy F-X, Danchenko N, Yarlas A, White MK, Rive B, et al. Psychometric validation
- 557 of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK
- 558 respondents with major depressive disorder. Neuropsychiatric Disease and Treatment.
- 559 2018;14:2861.
- 560 56. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue
- 561 measure: The Fatigue Assessment Scale. Journal of Psychosomatic Research. 2003;54(4):345-52.
- 57. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: a simple 562
- 563 measure of impairment in functioning. The British Journal of Psychiatry. 2002;180(5):461-4.
- 58.Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety 564 565
- 566 59. Ware JE, Kosinski M, Turner-Bowker D, Gandek B. How to score version 2 of the SF-12 (r)

disorder: the GAD-7. Archives of Internal Medicine. 2006;166(10):1092-7.

567 health survey. Lincoln, RI: Quality Metric. Inc, October. 2002.

- 568 60.Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ)
- and its correlates. British Journal of Clinical Psychology. 1982;21(1):1-16.
- 570 61. Qualtrics. Qualtrics. Provo, Utah, USA2020.
- 571 62.DiCicco-Bloom B, Crabtree BF. The qualitative research interview. Medical Education.
- 572 2006;40(4):314-21.
- 573 63.Britten N. Qualitative research: qualitative interviews in medical research. British Medical Journal.
- 574 1995;311(6999):251-3.
- 575 64. Archibald MM, Ambagtsheer RC, Casey MG, Lawless M. Using zoom videoconferencing for
- 576 qualitative data collection: perceptions and experiences of researchers and participants.
- 577 International Journal of Qualitative Methods. 2019;18:1609406919874596.
- 578 65.Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology.
  579 2006;3(2):77-101.
- 580 66.Braun V, Clarke V, Hayfield N. 'A starting point for your journey, not a map': Nikki Hayfield in
- 581 conversation with Virginia Braun and Victoria Clarke about thematic analysis. Qualitative
- 582 Research in Psychology. 2019:1-22.
- 583 67. Williams S. Chronic illness as biographical disruption or biographical disruption as chronic
- 584 illness? Reflections on a core concept. Sociology of Health & Illness. 2000;22(1):40-67.
- 585 68.Kelly MP, Field D. Medical sociology, chronic illness and the body. Sociology of Health &
- 586 Illness. 1996;18(2):241-57.
- 587
- 588
- 589 Figures
- 590 Figure 1: Flow chart showing the integration of STIMULATE-ICP DELPHI within overall
- 591 STIMULATE-ICP
- 592 Figure 2: Outline of Delphi Process

- 593 Figure 3: Filter model, expanded to conceptualise access to care for Long COVID or other
- 594 long-term conditions (LTCs) including medically not yet explained symptoms (MNYES) and
- 595 multi-morbidity

### STIMULATE-ICP Delphi study

SCIENCE DATASETS ANALYSIS To understand clinical outcomes depending on LongCOVIDilInesprofiles To understand effectiveness of current Long COVID care on physical and mental health outcomes	Goal: explore impact in terms of functioning, physical and mental health outcomes on course of Long COVID: of cardiac, neuropsychiatric and mast cell activation symptom profile of LTC comorbidity including mental disorders	Key Deliverables Data analysis of existing indicators; Inform Delphi study (below) Publications
EVIDENCE RCT To evaluate integrated care vs current care To understand outcomes depending on Long COVID illness profiles	Goal: RCT explore effect of intervention on physical, functioning, quality of life and mental health Long COVID outcomes	Key Deliverables Inform Delphi (below) Publication
To evaluate potential treatments Explore outcomes in treatment effect (depression, anxiety, cognition, functioning, QoL)		
CARE Qualitative study To evaluate interventions to reduce the inequalities in Long COVID care CARE Delphi To assess transferability of components of integrated care pathways (ICPs) to other long -term conditions	Goal - exploration of inequalities Goal - evaluate differences in uptake, adherence of ICPs in Long COVID and LTCs Explore if any inequalities exist in ICPs for other LTCs as well and suggest improvements	Key Deliverables Survey and interviews among patient participants in trials, Long COVID clinics and the community Survey among HCPs in Long COVID and other LTCs Publication and policy recommendations
	Synthesis, integration, dissemination	

Figure 1: Flow chart showing the integration of STIMULATE-ICP DELPHI within overall STIMULATE-ICP




Figure 2: Outline of Delphi Process



Filter 3:

GP reacts to the problem by providing offers of treatment in Primary care or referral to specialist service

Filter 2: GP recognises the problem

Filter 1:

Person recognises a problem and decides to seek help

Figure 3: Filter model, expanded to conceptualise access to care for Long COVID or other long-term conditions (LTCs) including medically not yet explained symptoms (MNYES) and multi-morbidity.